Sabine R de Wild, Lori M van Roozendaal, Johannes H W de Wilt, Thijs van Dalen, Jos A van der Hage, Frederieke H van Duijnhoven, Janine M Simons, Robert-Jan Schipper, Linda de Munck, Sander M J van Kuijk, Liesbeth J Boersma, Sabine C Linn, Marc B I Lobbes, Philip M P Poortmans, Vivianne C G Tjan-Heijnen, Koen K B T van de Vijver, Jolanda de Vries, A Helen Westenberg, Luc J A Strobbe, Marjolein L Smidt
BACKGROUND: Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in the sentinel lymph node. The aim of this registry study was to provide insight into the oncological safety of omitting completion axillary treatment in patients operated with mastectomy who have limited-volume sentinel lymph node metastasis. METHODS: Women diagnosed in 2013-2014 with unilateral cT1-2 N0 breast cancer treated with mastectomy, with one to three sentinel lymph node metastases (pN1mi-pN1a), were identified from the Netherlands Cancer Registry, and classified by axillary treatment: no completion axillary treatment, completion axillary lymph node dissection, regional radiotherapy, or completion axillary lymph node dissection followed by regional radiotherapy...
April 3, 2024: British Journal of Surgery